Natarajan Sethuraman Ph. D.

Natarajan Sethuraman Ph. D.

President of Research and DevelopmentatEntrada Therapeutics· In proxies 2022–2025

Pay in FY2025+15% from the year before · Entrada Therapeutics stock -40.5% the same year

Natarajan Sethuraman Ph. D. was paid $2.3M in FY2025 (Dec), up 15%. Entrada Therapeutics stock fell 40.5% that year.

Pay$100 in the stock at the end of FY21 → $60
Pay is from the Summary Compensation Table of each Entrada Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Entrada TherapeuticsPublic company · 4 yr
    • President of Research and Development2022 – Present · 4 yrStock in role -73%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?